Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 12 of 12 publications.

Poulos C, Ng X, Mansfield C, Rosenberg S, Peay H, Lee J, Irony T, Ho M. Logical soundness in a discrete choice experiment study of benefit risk preferences. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

DeMuro C. Two years of COVID-19: what has been the global impact on HRQoL and clinical outcomes? Presented at the Virtual ISPOR Europe 2021; November 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Turner AJ, Vass C. Matching techniques in stated preferences for health. Presented at the Virtual ISPOR Europe 2020 Conference; November 9, 2020. [abstract] Value Health. 2020 Dec; 23(Supplement 2):S758. doi: 10.1016/j.jval.2020.08.2086

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039

Dong OM, Lee CR, Wheeler S, Voora D, Dusetzina S, Wiltshire T. A cost-effectiveness analysis of multi-gene pharmacogenetic testing in acute coronary syndrome patients following percutaneous coronary intervention. Presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S6.

Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19 guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one year outcomes following percutaneous coronary intervention. Presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct 1; 20(9):A405. doi: 10.1016/j.jval.2017.08.041

Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, Lee CR, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May 1; 20(5):A276.

Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.

Basarir H, Pollard D, Brennan A, Elliott J, Heller S, Campbell MJ. The potential value of ongoing support in type-1 diabetes mellitus with dafneplus: exploratory pre-trial cost-effectiveness analysis on proposed trial end-point target for 12-month Hba1c improvement. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A350. doi: 10.1016/j.jval.2014.08.725

Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.

Twiss J, McKenna S, Crawford SR, Doward LC. Scaling properties of two commonly used outcome measures in dermatology – the Dermatology Life Quality Index (DLQI) and the Psoriasis Quality of Life Scale (PSORIQoL). Presented at the 13th Annual European Congress; November 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A244.